- Home
- ACRS vs DHY Comparison
ACRS vs DHY Comparison
Compare ACRS & DHY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- DHY
- Stock Information
- Founded
- ACRS 2012
- DHY 1998
- Country
- ACRS United States
- DHY United States
- Employees
- ACRS N/A
- DHY N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- DHY Finance/Investors Services
- Sector
- ACRS Health Care
- DHY Finance
- Exchange
- ACRS Nasdaq
- DHY Nasdaq
- Market Cap
- ACRS 230.8M
- DHY 216.5M
- IPO Year
- ACRS 2015
- DHY N/A
- Fundamental
- Price
- ACRS $2.85
- DHY $2.06
- Analyst Decision
- ACRS Strong Buy
- DHY
- Analyst Count
- ACRS 5
- DHY 0
- Target Price
- ACRS $9.75
- DHY N/A
- AVG Volume (30 Days)
- ACRS 1.4M
- DHY 569.1K
- Earning Date
- ACRS 11-06-2025
- DHY 01-01-0001
- Dividend Yield
- ACRS N/A
- DHY 9.10%
- EPS Growth
- ACRS N/A
- DHY N/A
- EPS
- ACRS N/A
- DHY N/A
- Revenue
- ACRS $15,742,000.00
- DHY N/A
- Revenue This Year
- ACRS N/A
- DHY N/A
- Revenue Next Year
- ACRS N/A
- DHY N/A
- P/E Ratio
- ACRS N/A
- DHY N/A
- Revenue Growth
- ACRS N/A
- DHY N/A
- 52 Week Low
- ACRS $1.05
- DHY $1.77
- 52 Week High
- ACRS $4.24
- DHY $2.08
- Technical
- Relative Strength Index (RSI)
- ACRS 67.71
- DHY 54.62
- Support Level
- ACRS $2.34
- DHY $1.99
- Resistance Level
- ACRS $2.57
- DHY $2.07
- Average True Range (ATR)
- ACRS 0.22
- DHY 0.02
- MACD
- ACRS 0.03
- DHY 0.00
- Stochastic Oscillator
- ACRS 96.18
- DHY 87.50
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.
About DHY Credit Suisse High Yield Bond Fund
Credit Suisse High Yield Bond Fund is a non-diversified, closed-end management investment company to seeks high current income and capital appreciation as a secondary objective.